Drug Profile
CNM Au 8
Alternative Names: Clean-surfaced gold nanocrystals; CNM-Au8; Gold nanocrystal suspension; Nanocrystalline goldLatest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Clene Nanomedicine
- Class Antiparkinsonians; Eye disorder therapies; Heavy metals
- Mechanism of Action Energy metabolism stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Amyotrophic lateral sclerosis
- Phase II/III Multiple sclerosis
- Phase II Optic nerve disorders; Parkinson's disease
Most Recent Events
- 17 Apr 2024 Updated efficacy data from a phase II/III VISIONARY-MS long term extension (VISIONARY-MS LTE) trial in multiple sclerosis released by Clene Nanomedicine
- 15 Mar 2024 Pharmacodynamics data from a preclinical mechanism of action study released by Clene
- 15 Mar 2024 Clene Nanomedicine plans a registrational phase III trial for Neurodegenerative disorders and Amyotrophic lateral sclerosis in 2024